TY - JOUR
T1 - Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients with COVID-19
AU - Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group
AU - Gupta, Neha
AU - Settle, Lisa
AU - Brown, Brent R.
AU - Armaignac, Donna L.
AU - Baram, Michael
AU - Perkins, Nicholas E.
AU - Kaufman, Margit
AU - Melamed, Roman R.
AU - Christie, Amy B.
AU - Danesh, Valerie C.
AU - Denson, Joshua L.
AU - Cheruku, Sreekanth R.
AU - Boman, Karen
AU - Kumar, Vishakha K.
AU - Bansal, Vikas
AU - Kashyap, Rahul
AU - Walkey, Allan J.
AU - Domecq, Juan P.
AU - Aston, Christopher E.
AU - Mesland, Jean Baptiste
AU - Henin, Pierre
AU - Petre, Hélène
AU - Buelens, Isabelle
AU - Gerard, Anne Catherine
AU - Clevenbergh, Philippe
AU - Granado, Rolando Claure Del
AU - Mercado, Jose A.
AU - Vega-Terrazas, Esdenka
AU - Iturricha-Caceres, Maria F.
AU - Garza, Ruben
AU - Chu, Eric
AU - Chan, Victoria
AU - Gavidia, Oscar Y.
AU - Pachon, Felipe
AU - Sanchez, Yeimy A.
AU - Knežević, Danijel
AU - El Kassas, Mohamed
AU - Badr, Mohamed
AU - Tawheed, Ahmed
AU - Yahia, Hend
AU - Kantas, Dimitrios
AU - Koulouras, Vasileios
AU - Pineda, Estela
AU - Reyes Guillen, Gabina María
AU - Soto, Helin Archaga
AU - Vallecillo Lizardo, Ana Karen
AU - Kopitkó, Csaba
AU - Shlomovich, Mark
AU - Gupta, Manoj K.
AU - Hope, Aluko
N1 - Funding Information:
Dr. Perkins received funding from TelmedIQ. Dr. Kaufman’s institution received funding from the Society of Critical Care Medicine, and she received funding from consulting for Mendaera. Dr. Christie’s institution received funding from Navicent Health Foundation. Ms. Boman, Drs. Kumar’s, Walkey’s, and Kashyap’s institutions received funding from the Gordon and Betty Moore Foundation. Ms. Boman, Drs. Kumar’s, and Kashyap’s institutions received funding from Janssen R & D. Dr. Aston’s institution received funding from the National Institutes of Health. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Funding Information:
Supported, in part, by National Institutes of Health/ National Center for Research Resources/National Center for Advancing Translational Sciences' Clinical and Translational Science Award Grant Number UL1 TR002377 (Research Electronic Data Capture), U54 GM104940 which funds the Louisiana Clinical and Translational Science Center Roadmap Scholars Award (to Dr. Denson), American Diabetes Association COVID-19 Research Award 7-20-COVID-053 (to Dr. Denson), the Society of Critical Care Medicine (to Dr. Denson), the Gordon and Betty Moore Foundation (to Dr. Denson), and Janssen Research & Development, LLC (to Drs. Boman, Kumar, and Kashyap).
Publisher Copyright:
Copyright © 2022 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
PY - 2022/10/1
Y1 - 2022/10/1
N2 - OBJECTIVES: To determine the association of prior use of renin-angiotensin-aldosterone system inhibitors (RAASIs) with mortality and outcomes in hospitalized patients with COVID-19. DESIGN: Retrospective observational study. SETTING: Multicenter, international COVID-19 registry. SUBJECTS: Adult hospitalized COVID-19 patients on antihypertensive agents (AHAs) prior to admission, admitted from March 31, 2020, to March 10, 2021. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Data were compared between three groups: patients on RAASIs only, other AHAs only, and those on both medications. Multivariable logistic and linear regressions were performed after controlling for prehospitalization characteristics to estimate the effect of RAASIs on mortality and other outcomes during hospitalization. Of 26,652 patients, 7,975 patients were on AHAs prior to hospitalization. Of these, 1,542 patients (19.3%) were on RAASIs only, 3,765 patients (47.2%) were on other AHAs only, and 2,668 (33.5%) patients were on both medications. Compared with those taking other AHAs only, patients on RAASIs only were younger (mean age 63.3 vs 66.9 yr; p < 0.0001), more often male (58.2% vs 52.4%; p = 0.0001) and more often White (55.1% vs 47.2%; p < 0.0001). After adjusting for age, gender, race, location, and comorbidities, patients on combination of RAASIs and other AHAs had higher in-hospital mortality than those on RAASIs only (odds ratio [OR] = 1.28; 95% CI [1.19-1.38]; p < 0.0001) and higher mortality than those on other AHAs only (OR = 1.09; 95% CI [1.03-1.15]; p = 0.0017). Patients on RAASIs only had lower mortality than those on other AHAs only (OR = 0.87; 95% CI [0.81-0.94]; p = 0.0003). Patients on ACEIs only had higher mortality compared with those on ARBs only (OR = 1.37; 95% CI [1.20-1.56]; p < 0.0001). CONCLUSIONS: Among patients hospitalized for COVID-19 who were taking AHAs, prior use of a combination of RAASIs and other AHAs was associated with higher in-hospital mortality than the use of RAASIs alone. When compared with ARBs, ACEIs were associated with signifcantly higher mortality in hospitalized COVID-19 patients.
AB - OBJECTIVES: To determine the association of prior use of renin-angiotensin-aldosterone system inhibitors (RAASIs) with mortality and outcomes in hospitalized patients with COVID-19. DESIGN: Retrospective observational study. SETTING: Multicenter, international COVID-19 registry. SUBJECTS: Adult hospitalized COVID-19 patients on antihypertensive agents (AHAs) prior to admission, admitted from March 31, 2020, to March 10, 2021. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Data were compared between three groups: patients on RAASIs only, other AHAs only, and those on both medications. Multivariable logistic and linear regressions were performed after controlling for prehospitalization characteristics to estimate the effect of RAASIs on mortality and other outcomes during hospitalization. Of 26,652 patients, 7,975 patients were on AHAs prior to hospitalization. Of these, 1,542 patients (19.3%) were on RAASIs only, 3,765 patients (47.2%) were on other AHAs only, and 2,668 (33.5%) patients were on both medications. Compared with those taking other AHAs only, patients on RAASIs only were younger (mean age 63.3 vs 66.9 yr; p < 0.0001), more often male (58.2% vs 52.4%; p = 0.0001) and more often White (55.1% vs 47.2%; p < 0.0001). After adjusting for age, gender, race, location, and comorbidities, patients on combination of RAASIs and other AHAs had higher in-hospital mortality than those on RAASIs only (odds ratio [OR] = 1.28; 95% CI [1.19-1.38]; p < 0.0001) and higher mortality than those on other AHAs only (OR = 1.09; 95% CI [1.03-1.15]; p = 0.0017). Patients on RAASIs only had lower mortality than those on other AHAs only (OR = 0.87; 95% CI [0.81-0.94]; p = 0.0003). Patients on ACEIs only had higher mortality compared with those on ARBs only (OR = 1.37; 95% CI [1.20-1.56]; p < 0.0001). CONCLUSIONS: Among patients hospitalized for COVID-19 who were taking AHAs, prior use of a combination of RAASIs and other AHAs was associated with higher in-hospital mortality than the use of RAASIs alone. When compared with ARBs, ACEIs were associated with signifcantly higher mortality in hospitalized COVID-19 patients.
KW - COVID-19
KW - antihypertensive agents
KW - mortality
KW - outcome
KW - renin-angiotensin-aldosterone system inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85138445319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138445319&partnerID=8YFLogxK
U2 - 10.1097/CCM.0000000000005627
DO - 10.1097/CCM.0000000000005627
M3 - Article
C2 - 35894609
AN - SCOPUS:85138445319
VL - 50
SP - E744-E758
JO - Critical Care Medicine
JF - Critical Care Medicine
SN - 0090-3493
IS - 10
ER -